Crossmark

GLP-1-Rezeptor-Agonisten im Vergleich mit SGLT-2-Inhibitoren

Published Online: 2020-06-19

Published Print: 2020-07

Authors

Pavlicek, Vojtech
License Information

Text and Data Mining valid from 2020-06-19

Version of Record valid from 2020-06-19
More Information

Article History

First Online: 19 June 2020

Interessenkonflikt

: V. Pavlicek: Advisory Boards für MSD, Sanofi Aventis, Novo Nordisk, AstraZeneca, Boeringer Ingelheim, Eli-Lilly.

Document is current